Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 33.56
Key Takeaways
Risk factor
High price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of biological products in China and internationally. The company offers its products for auto-immune, oncology, ophthalmologic, and infectious diseases, as well as metabolic disorders, etc. It offers JUNMAIKANG, an autoimmune Adalimumab injection. The company’s oncology products pipeline includes...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Data is available to registered users only
Buy
Sell